Rigel Pharmaceuticals (RIGL) Stock Forecast & Price Target

Rigel Pharmaceuticals is supported by a rapidly broadening commercial base, with Tavalisse and Rezlidhia driving continued growth, Gavreto adding durable oncology evidence, and Veppanu now expanding the portfolio as a fourth product and potential new growth engine. The Veppanu launch is especially compelling because it is the first and only FDA-approved PROTAC, targets the 20,000 U.S. patients in the 2L/3L ER+/HER2- ESR1-mutated setting, and could become Rigel’s largest commercial product while leveraging existing commercial infrastructure. Fundamental upside is further reinforced by ex-U.S. Rezlidhia momentum through the Japan NDA filing, the $10M upfront plus up to $152.5M in milestones from Kissei, and R289’s $3.41/share clinical NPV contribution with a modeled $250M peak-sales opportunity.

Rigel Pharmaceuticals is facing a negative fundamental setup because its valuation is concentrated in a small number of marketed assets, with Tavalisse contributing 62%, Rezlidhia 27%, and Gavreto 11%, while VEPPANU and pipeline programs are excluded from the model. Weak commercial execution across Tavalisse, Gavreto, and Rezlidhia, along with uncertainty around pricing, launch uptake, and reimbursement, could limit revenue durability, while failed or inconclusive clinical trials and funding constraints add further downside risk. The safety profile of pralsetinib is also a concern, with 71.3% any-grade infections, 28.7% grade ≥3 infections, and 8 fatal infection events versus none with SOC, underscoring meaningful regulatory and adoption risk.